Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Offer

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Jul 25, 2023 8:08am

186 Views

Post# 35555520

RE:Offer

You know ATE almost sold the IBD molecule ... once-upon-a-time.
In the days of Leeman Brothers.

Is that what you're talking about ?

I'm not going to assume there will be any offers or acquisitions. That will take care of itself one day.

First - we need to get through P2-acute.
We need to know a chronic plan, or a chronic flare-up plan.
We need money to flow re. partnerships in order to pay for moving the pipeline forward.
That all waits for OTENA. IMO

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario